ITBMed - About the company
ITBMed is a series A company based in Stockholm (Sweden), founded in 2016 by David Berglund, Erik Berglund and David Sachs. It operates as a Developer of monoclonal antibodies to prevent transplant rejections. ITBMed has raised $87M in funding from 3E Bioventures Capital and Yonjin Capital. The company has 774 active competitors, including 180 funded and 177 that have exited. Its top competitors include companies like BeiGene, Biogen and argenx.
Company Details
Developer of monoclonal antibodies to prevent transplant rejections. The company is developing a humanized IgG1K antibody, Siplizumab which targets human CD2 molecules. The antibody binds to the human CD2 receptor found on T lymphocytes (T cells), natural killer cells, and thymocytes to inhibit their activation. The lead candidate Siplizumab is in the pivotal stage of the clinical trial for solid organ transplantation, and bone marrow transplantation.
- Website
- itb-med.com
- Email ID
- *****@itb-med.com
- Phone Number
- +46 **********
Key Metrics
Founded Year
2016
Location
Stockholm, Sweden
Stage
Series A
Total Funding
$87M in 2 rounds
Latest Funding Round
Investors
Ranked
118th among 774 active competitors
Employee Count
44 as on Sep 30, 2026
Legal entities associated with ITBMed
ITBMed is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ITB-Med AB CIN: 559017-9429 , Sweden, Active | $0 - $1M (As on Dec 31, 2018) | - | - |
Sign up to download ITBMed's company profile
ITBMed's funding and investors
ITBMed has raised a total funding of $87M over 2 rounds. Its first funding round was on Apr 02, 2018. Its latest funding round was a Series A round on Dec 01, 2021 for $*****. 3 investors participated in its latest round. ITBMed has 3 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of ITBMed:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 01, 2021 | 7826878 | Series A | 4145323 | 9186901 | 1014664 | 1844425 |
Apr 02, 2018 | 6382899 | Angel | 1604775 | 7519716 | 2450655 |
Access funding benchmarks and valuations. Sign up today!View details of ITBMed's funding rounds and investors
ITBMed's founders and board of directors
Founder? Claim ProfileThe founders of ITBMed are David Berglund, Erik Berglund and David Sachs. Erik Berglund is the CEO of ITBMed.
Here are the details of ITBMed's key team members:
- David Berglund: Co-Founder of ITBMed and founder of 1 other company. Contact Info: 1 email address
- Erik Berglund: Co-Founder & CEO of ITBMed. Contact Info: 1 email address
- David Sachs: Co-Founder of ITBMed.
View details of ITBMed's Founder profiles and Board Members
ITBMed's employee count trend
ITBMed has 44 employees as of Sep 26. Here is ITBMed's employee count trend over the years:
Uncover ITBMed's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ITBMed's Competitors and alternates
Top competitors of ITBMed include BeiGene, Biogen and argenx. Here is the list of Top 10 competitors of ITBMed, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
4th |  CareDx 1998, Brisbane (United States), Public | Developer of medical solutions for transplant patients | $138M | 73/100 | |
5th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
6th |  Abcellera Biologics 2012, Vancouver (Canada), Public | AI-enabled platform for antibodies discovery | $115M | 71/100 | |
7th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 69/100 | ||
8th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of bispecific T cell receptor therapies for human diseases | $601M | 69/100 | |
9th | ADMA Biologics 2005, Ramsey (United States), Public | Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases | $17.6M | 68/100 | |
10th |  Nimbus Therapeutics 2009, Cambridge (United States), Series F | Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases | $637M | 68/100 | |
118th | Developer of monoclonal antibodies to prevent transplant rejections | $87M | 51/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ITBMed's competitors? Click here to see the top ones
ITBMed's Investments and acquisitions
ITBMed has made no investments or acquisitions yet.
Reports related to ITBMed
Here is the latest report on ITBMed's sector:
News related to ITBMed
•
Tianmaiyuan and completed iTAb™ spin-off and A-round financingBusiness Wire•Dec 01, 2021•ITabMed, Evive Biotech, ITBMed
•
ITBMed announces the completion of an equity investment of up to $67 millionPR Newswire•Apr 04, 2018•ITBMed, Pablo Legorreta
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ITBMed
Explore our recently published companies
- Octewya - Unfunded company
- KYC Lookup - United Kingdom based, 2017 founded, Unfunded company
- Saint MGMT - Richmond based, 2016 founded, Unfunded company
- Gramotthan Balika - India based, 2016 founded, Unfunded company
- CIL AND FRAY GIDA - Turkey based, 2016 founded, Unfunded company
- Colleen The Realtor - Unfunded company
